European journal of drug metabolism and pharmacokinetics · 2026
JLP-2008 Fixed-Dose Combination Tablet Demonstrates Bioequivalence and Comparable Safety to Separate Dapagliflozin + Pioglitazone in Healthy Participants.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roh Woo-Lee, Shin Wonsuk, Yoo Hyounggyoon, Ahn Kwang Hyun, Lee Yilseob, Kim Anhye
Аннотация
BACKGROUND AND OBJECTIVES: To establish pharmacokinetic bioequivalence and assess the safety of a single-dose administration of fixed-dose combination (FDC) tablet containing dapagliflozin 10 mg + pioglitazone 15 mg (JLP-2008) compared with a single-dose administration of their individual tablets.
METHODS: In this randomized, open-label, two-period crossover study, 49 healthy Korean adults were enrolled, 48 received at least one dose and 45 completed both periods. Participants received either one JLP-2008 tablet or separate dapagliflozin + pioglitazone tablets under fasting conditions, then the alternate treatment after a 7-day washout. Blood samples collected predose to 48 h were quantified by ultra-fast liquid chromatography-tandem mass spectrometry. Primary endpoints were maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from zero until the last measurable concentration (AUClast) for each analyte; bioequivalence was concluded if 90% confidence intervals (CIs) for test/reference geometric mean ratios (GMRs) lay within 80.00-125.00%. Adverse events (AEs), vital signs, laboratories, blood glucose, and 12-lead electrocardiogram (ECGs) were monitored for safety assessment.
RESULTS: Dapagliflozin and pioglitazone met bioequivalence criteria: GMRs (90% CIs) were 1.04 (0.95-1.15) for dapagliflozin Cmax, 1.05 (1.02-1.08) for dapagliflozin AUClast, 0.94 (0.85-1.04) for pioglitazone Cmax and 0.93 (0.87-1.00) for pioglitazone AUClast, each within the 80.00-125.00% acceptance range. Hydroxy pioglitazone (M-IV), an active metabolite, also met the criteria: Cmax, 0.94 (0.89-1.00) and AUClast, 0.93 (0.88-0.98). Twenty-seven treatment-emergent AEs were recorded (test = 13 in 9 participants; reference = 14 in 9 participants); all were mild or moderate, non-serious, and incidence did not differ between treatments. No clinically meaningful hypoglycemia, ECG changes, or laboratory abnormalities were observed.
CONCLUSION: JLP-2008 delivers systemic exposures to dapagliflozin and pioglitazone equivalent to those from co-administration of individual tablet and is well tolerated. FDC may provide a more convenient treatment option for patients with type 2 diabetes mellitus (T2DM), and its use was supported by comparable pharmacokinetic and safety profiles.
STUDY REGISTRATION: ClinicalTrials.gov (NCT06165965; retrospectively registered on 07 December 2023).
METHODS: In this randomized, open-label, two-period crossover study, 49 healthy Korean adults were enrolled, 48 received at least one dose and 45 completed both periods. Participants received either one JLP-2008 tablet or separate dapagliflozin + pioglitazone tablets under fasting conditions, then the alternate treatment after a 7-day washout. Blood samples collected predose to 48 h were quantified by ultra-fast liquid chromatography-tandem mass spectrometry. Primary endpoints were maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from zero until the last measurable concentration (AUClast) for each analyte; bioequivalence was concluded if 90% confidence intervals (CIs) for test/reference geometric mean ratios (GMRs) lay within 80.00-125.00%. Adverse events (AEs), vital signs, laboratories, blood glucose, and 12-lead electrocardiogram (ECGs) were monitored for safety assessment.
RESULTS: Dapagliflozin and pioglitazone met bioequivalence criteria: GMRs (90% CIs) were 1.04 (0.95-1.15) for dapagliflozin Cmax, 1.05 (1.02-1.08) for dapagliflozin AUClast, 0.94 (0.85-1.04) for pioglitazone Cmax and 0.93 (0.87-1.00) for pioglitazone AUClast, each within the 80.00-125.00% acceptance range. Hydroxy pioglitazone (M-IV), an active metabolite, also met the criteria: Cmax, 0.94 (0.89-1.00) and AUClast, 0.93 (0.88-0.98). Twenty-seven treatment-emergent AEs were recorded (test = 13 in 9 participants; reference = 14 in 9 participants); all were mild or moderate, non-serious, and incidence did not differ between treatments. No clinically meaningful hypoglycemia, ECG changes, or laboratory abnormalities were observed.
CONCLUSION: JLP-2008 delivers systemic exposures to dapagliflozin and pioglitazone equivalent to those from co-administration of individual tablet and is well tolerated. FDC may provide a more convenient treatment option for patients with type 2 diabetes mellitus (T2DM), and its use was supported by comparable pharmacokinetic and safety profiles.
STUDY REGISTRATION: ClinicalTrials.gov (NCT06165965; retrospectively registered on 07 December 2023).